Results from a study presented today at the ESC Congress 2011, show that TAVI implantation in low risk patients, met with 100% procedural success (versus 95.3% in the high Euroscore group (p=0.1).
Aortic stenosis is the most frequently acquired valve disease in adults. 2% are symptomatic and thus should require aortic valve replacement because, in this disease, a long latency is followed by rapid progression after the appearance of symptoms, with more than half of patients dying within two years. It can be estimated that with the aging population, within 15 years, the number of aortic stenosis patients will double.
After more than 15 years of research, the first-in-man percutaneous valve implantation was performed in our center at the University Hospital of Rouen by Prof. Cribier in April 2002. Since then, about 40 000 patients have been implanted worldwide with the use of two different models of valve: the balloon expandable valve 1 and the self expanding device 2. The CE mark was obtained for both in 2007. TAVI can today be proposed as an alternative treatment and has recently demonstrated its great efficiency with the results of the pivotal PARNER-US trial.
Based on the recommendations of both the European Society of Cardiology and the European Society of Cardiac Surgery, most of the registries have so far only included patients with high logistic Euroscore > 20%. (a system developed to predict the operative mortality of coronary surgery).
In view of the overall good results in this high risk population, a significant trend to include lower risk patients in Europe has been observed. The last registries have seen their Euroscore decreasing to 15% and some prospective trials are planned to include patients whatever their Score.
"We sought to evaluate the results obtained in our subgroup of patients with a low Euroscore. It does not mean that the patients were at very low risk for TAVI, since they had been considered as having surgical contraindication which did not affect the Euroscore (radiotherapy, corticosteroids, thoracic deformation or porcelain aorta). However, the patients were often less sick and younger and it seemed interesting to assess the results in this population," said Dr Godin.This study is a retrospective study from all 177 patients implanted with the Edwards prosthesis at the Rouen centre between May 2006 and January 2011. Patients were divided into two groups according to their predictive Logistic Euroscore: High Euroscore (>20%) vs Low Euroscore (
Results show that procedural success was 100% in the low Euroscore group versus 95.3% in the high Euroscore group (p=0.1).The most interesting point to observe is the absence of death at one month in the low Euroscore group, versus a mortality rate of 11.1% in the high Euroscore group (>20%), (p
While we were expecting a lower mortality among patients with low Euroscore, the observed difference was much greater than anticipated. In fact the mortality rates have approached the results with conventional surgery.
The results represent a first step towards a broader assessment of percutaneous techniques in populations at lower surgical risk but without forgetting that surgery is currently the gold standard
Dr Matthieu Godin, Pr Hélène Eltchaninoff, Pr Alain Cribier1 (Edwards SAPIEN and more recently SAPIEN-XT) developed by the company Edwards Lifesciences
2 The Medtronic CoreValve
About the European Society of Cardiology
The European Society of Cardiology (ESC) represents more than 71,200 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.
About ESC Congress 2011
ESC Congress 2011 will take place from 27 August to 31 August at Paris Nord Villepinte, Paris. Information on the scientific programme is available at http://spo.escardio.org/Welcome.aspx?eevtid=48 More information on ESC Congress 2011 is available from the ESC's press office at firstname.lastname@example.org
Jacqueline Partarrieu | EurekAlert!
'Memtransistor' brings world closer to brain-like computing
22.02.2018 | Northwestern University
MRI technique differentiates benign breast lesions from malignancies
20.02.2018 | Radiological Society of North America
A newly developed laser technology has enabled physicists in the Laboratory for Attosecond Physics (jointly run by LMU Munich and the Max Planck Institute of Quantum Optics) to generate attosecond bursts of high-energy photons of unprecedented intensity. This has made it possible to observe the interaction of multiple photons in a single such pulse with electrons in the inner orbital shell of an atom.
In order to observe the ultrafast electron motion in the inner shells of atoms with short light pulses, the pulses must not only be ultrashort, but very...
A group of researchers led by Andrea Cavalleri at the Max Planck Institute for Structure and Dynamics of Matter (MPSD) in Hamburg has demonstrated a new method enabling precise measurements of the interatomic forces that hold crystalline solids together. The paper Probing the Interatomic Potential of Solids by Strong-Field Nonlinear Phononics, published online in Nature, explains how a terahertz-frequency laser pulse can drive very large deformations of the crystal.
By measuring the highly unusual atomic trajectories under extreme electromagnetic transients, the MPSD group could reconstruct how rigid the atomic bonds are...
Quantum computers may one day solve algorithmic problems which even the biggest supercomputers today can’t manage. But how do you test a quantum computer to...
For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.
In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...
Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale
Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...
15.02.2018 | Event News
13.02.2018 | Event News
12.02.2018 | Event News
23.02.2018 | Physics and Astronomy
23.02.2018 | Health and Medicine
23.02.2018 | Physics and Astronomy